Table 1.

Representative antiangiogenic drugs for the therapy of cancer.

Classification of common drugs	Drugs	Mechanism of action	Type of cancer
VEGF neutralising antibody	Bevacizumab	Humanised VEGF-A antibody	Non-small cell lung cancer, renal cell carcinoma, colorectal cancer, ovarian cancer, breast cancer, cervical cancer, and glioblastoma.
Anti-VEGFR antibodies that block the interaction of VEGF with its receptor	Ramucirumab	Humanised VEGFR2 antibody	Advanced gastric cancer or gastroesophageal junction adenocarcinoma, metastatic non-small cell lung cancer and cancers with EFGR or ALK gene mutations
Competitive receptor drugs	Ziv-aflibercept	Fusion proteins, which act directly on VEGF-A, VEGF-B, and PIGF	Patients with metastatic colorectal cancer
Small molecule TKIs	Imatinib	Multiple tyrosine kinase inhibitors	Chronic myeloid leukaemia and Malignant gastrointestinal stromal cancers
	Sorafenib	Multiple tyrosine kinase inhibitors	Liver cancer, kidney cancer, and thyroid cancer
	Sunitinib	Multiple tyrosine kinase inhibitors	Gastrointestinal stromal cancers (GIST), advanced renal cell carcinoma (RCC), and pancreatic neuroendocrine cancers (pNET)
Broad-spectrum vascular endothelial factor inhibitors	Endostar	Inhibits vascular endothelial cells	Advanced non-small cell lung cancer